Precision receives CTA approval to expand ELIMINATE-B study

​Precision BioSciences has received clinical trial application (CTA) approval to expand its global ELIMINATE-B study of PBGENE-HBV, an in vivo gene editing therapy for chronic hepatitis B.

The post Precision receives CTA approval to expand ELIMINATE-B study appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Philips secures FDA clearance for Verida spectral CT system
First patient receives JANX014 dose in Janux’s trial for mCRPC
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Phantom Neuro secures approval for muscle-machine interface trial
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us